Companies ImmunityBio, Inc.
ImmunityBio (IBRX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me ImmunityBio, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers67th pct.Of 12 peer CEOs
CEO pay, last three years
- $1,156,903FY2023
- $10,954,875FY2024
- $12,716,953FY2025
CEO total pay was $12,716,953 in fiscal 2025, up from $10,954,875 in fiscal 2024.
FY2025: salary $831,667 · bonus $141,684 · stock awards $2,787,828 · option awards $8,353,406
Executives and directors
Regan Lauer · Chief Accounting OfficerRichard Adcock · CEODavid Sachs · CFOPatrick Soon-Shiong · ExecutiveBarry J. Simon · DirectorBruce Wendel · Independent DirectorCheryl L. Cohen · Lead Independent DirectorChristobel Selecky · Independent DirectorJohn Owen Brennan · Former director (through FY2025)Linda Maxwell · Independent DirectorMichael D. Blaszyk · Independent DirectorWesley Clark · Independent Director
Frequently asked questions
Who was the highest-paid executive at ImmunityBio, Inc. in fiscal 2025?
As disclosed, Richard Adcock (President and CEO) was the highest-paid executive at ImmunityBio, Inc. in fiscal 2025, with total compensation of $12,716,953.
How does ImmunityBio, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Richard Adcock's total compensation ranked at the 67th percentile of ImmunityBio, Inc.'s disclosed peer group.
What is ImmunityBio, Inc.'s CEO-to-median employee pay ratio?
As disclosed, ImmunityBio, Inc.'s CEO-to-median employee pay ratio was 69:1.
How did shareholders vote on ImmunityBio, Inc.'s executive compensation?
As disclosed, 98.94% of shareholders supported ImmunityBio, Inc.'s executive compensation in the latest say-on-pay vote.
How much does ImmunityBio, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, ImmunityBio, Inc. reported total board compensation of $739,878 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Adcock | $831,667 | $141,684 | $2,787,828 | $8,353,406 | $485,166 | $0 | $117,202 | $12,716,953 |
| President and CEO | ||||||||
| Patrick Soon-Shiong | 648,826 | 110,535 | 2,787,828 | 8,353,406 | 378,503 | 0 | 14,157 | 12,293,255 |
| Founder, Executive Chairman of the Board and Global Chief Scientific and Medical Officer | ||||||||
| David Sachs | 591,711 | 66,974 | 836,347 | 2,506,022 | 229,336 | 0 | 14,153 | 4,244,543 |
| CFO | ||||||||
| Regan Lauer | 338,773 | 38,344 | 55,755 | 167,068 | 131,302 | 0 | 14,071 | 745,313 |
| Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Richard Adcock | $12,716,953 | $10,954,875 | $1,156,903 | ↑ +1,762,078 |
| Patrick Soon-Shiong | 12,293,255 | 8,220,694 | 865,340 | ↑ +4,072,561 |
| David Sachs | 4,244,543 | 3,381,607 | 1,058,082 | ↑ +862,936 |
| Regan Lauer | 745,313 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee believes the substantial majority of NEO compensation should be at-risk and performance-based to align executive interests with stockholder returns and support the company's business mission. The program targets compensation levels consistent with the market median, adjusting for experience and talent criticality, while emphasizing long-term equity compensation to foster an ownership mindset.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Richard Adcock | RSU | 2025-02-10 | — | — | 822,368 | — | $2,787,828 |
| Regan Lauer | RSU | 2025-02-10 | — | — | 16,447 | — | 55,755 |
| Patrick Soon-Shiong | RSU | 2025-02-10 | — | — | 822,368 | — | 2,787,828 |
| David Sachs | RSU | 2025-02-10 | — | — | 246,710 | — | 836,347 |
| Regan Lauer | OPTION | 2025-02-10 | — | — | 56,250 | — | 167,068 |
| David Sachs | OPTION | 2025-02-10 | — | — | 843,750 | — | 2,506,022 |
| Richard Adcock | OPTION | 2025-02-10 | — | — | 2,812,500 | — | 8,353,406 |
| Patrick Soon-Shiong | OPTION | 2025-02-10 | — | — | 2,812,500 | — | 8,353,406 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Richard Adcock | $2,787,828 | $0 | $8,353,406 | 0.0% |
| Regan Lauer | 55,755 | 0 | 167,068 | 0.0% |
| Patrick Soon-Shiong | 2,787,828 | 0 | 8,353,406 | 0.0% |
| David Sachs | 836,347 | 0 | 2,506,022 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Regan Lauer | RSU | 8,130 | — | $16,097 |
| Regan Lauer | RSU | 16,447 | — | 32,565 |
| Regan Lauer | Option | 28,293 | 5.24 | — |
| David Sachs | RSU | 45,602 | — | 90,292 |
| Richard Adcock | RSU | 51,731 | — | 102,427 |
| Regan Lauer | Option | 56,250 | 3.39 | — |
| David Sachs | RSU | 81,301 | — | 160,976 |
| Patrick Soon-Shiong | RSU | 228,658 | — | 452,743 |
| David Sachs | RSU | 246,710 | — | 488,486 |
| David Sachs | Option | 282,927 | 5.24 | — |
| Richard Adcock | RSU | 304,878 | — | 603,658 |
| Patrick Soon-Shiong | Option | 795,732 | 5.24 | — |
| Richard Adcock | RSU | 822,368 | — | 1,628,289 |
| Patrick Soon-Shiong | RSU | 822,368 | — | 1,628,289 |
| David Sachs | Option | 843,750 | 3.39 | — |
| Richard Adcock | Option | 1,060,976 | 5.24 | — |
| Richard Adcock | Option | 2,812,500 | 3.39 | — |
| Patrick Soon-Shiong | Option | 2,812,500 | 3.39 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Cheryl L. CohenIndependent · Lead Independent Director · Audit · Nominating and Corporate Governance | $114,192 | $0 | $400,000 | $0 | $0 | $514,192 |
| Michael D. BlaszykIndependent · Audit (Chair) · Compensation | 113,384 | 0 | 400,000 | 0 | 0 | 513,384 |
| Linda MaxwellIndependent · Audit · Compensation (Chair) | 89,192 | 0 | 400,000 | 0 | 0 | 489,192 |
| Christobel SeleckyIndependent · Audit · Compensation | 77,281 | 0 | 400,000 | 0 | 0 | 477,281 |
| Wesley ClarkIndependent · Nominating and Corporate Governance | 70,589 | 0 | 400,000 | 0 | 0 | 470,589 |
| Bruce WendelIndependent · Related Party Transaction · Partial-year service | 2,740 | 0 | 300,000 | 0 | 0 | 302,740 |
| John Owen BrennanIndependent · Audit · Compensation · Related Party Transaction · Not standing for re-election · Departed during FY | 0 | 0 | 0 | 0 | 272,500 | 272,500 |
| Barry J. SimonEmployee director · Partial-year service | 0 | 0 | 0 | — | 0 | 0 |
| Patrick Soon-ShiongEmployee director · Board Chair · Nominating and Corporate Governance (Chair) · Partial-year service | 0 | 0 | 0 | — | 0 | 0 |
| Richard AdcockEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 12,500 / 10,000 / 7,500 |
| Stock ownership guideline | $3 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $467,378 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $272,500 |
| Total cost of the board | $739,878 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ImmunityBio as a peer
Companies that benchmark against IBRX
13 companies name IBRX as a compensation peer
The list of companies that name IBRX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
BBIO BridgeBio Pharma, Inc.NBIX Neurocrine Biosciences, Inc.NVAX Novavax, Inc.RCUS Arcus Biosciences, Inc.BPMC Blueprint Medicines CorporationSNDX Syndax Pharmaceuticals, Inc.TGTX TG Therapeutics, Inc.ALLO Allogene Therapeutics, Inc.FATE Fate Therapeutics, Inc.KURA Kura Oncology, Inc.RARE Ultragenyx Pharmaceutical Inc.IMCR Immunocore Holdings plc
Peer reciprocity
The companies ImmunityBio, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics, Inc. | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 3 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 4 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 5 | ImmunityBio, Inc. | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 6 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 7 | Immunocore Holdings plc | 2025 | Bahija Jallal | 765,000 | 2,819,992 | 6,579,990 | 688,500 | 10,885,268 |
| 8 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 9 | Novavax, Inc. | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 10 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 11 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 12 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 13 | Fate Therapeutics, Inc. | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| ImmunityBio, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Fate Therapeutics, Inc. | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Immunocore Holdings plc | 120% | Option 70 · RSU 30 | not disclosed | Aon Human Capital Solutions practice, a division of Aon plc |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Neurocrine Biosciences, Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Novavax, Inc. | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| TG Therapeutics, Inc. | 131% | RSU 100 | No | Compensia, Inc. |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-11 | 556,683,366 | 2,530,858 | 3,430,808 | 98.94% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-11 | 98.94%a |
a. Approved under the standard stated in the filing — “As a result, abstentions will be counted for purposes of determining the presence or absence of a quorum and will also count as votes against a proposal in cases where approval of the proposal requires the affirmative vote of a majority of the shares present live via the Internet or represented by proxy and entitled to vote at the Annual Meeting, including Proposal 4.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 69 : 1 |
|---|---|
| CEO total compensation | $12,716,953 |
| Median employee compensation | $183,848 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Barry J. Simon | Director | 2026-06-04 | D | 23,033 | $7 | $165,306 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wesley Clark | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Linda Maxwell | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Wendel | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael D. Blaszyk | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry J. Simon | Director | 2026-06-24 | D | 25,000 | 8 | 196,908 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | A | 32,173 | 3 | 95,876 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 33,549 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 32,173 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 95,722 | 9 | 862,216 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | A | 30,000 | 3 | 85,200 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | A | 33,549 | 3 | 100,312 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-30 | A | 700 | 3 | 2,086 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-30 | — | 1,000 | — | — | 1 insider, 2 accrual rows | ||
| Christobel Selecky | Director | 2026-06-30 | D | 1,000 | 9 | 9,000 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-30 | A | 300 | 3 | 897 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | D | 35,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | D | 159,478 | 9 | 1,439,066 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | A | 124,414 | 3 | 371,998 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | D | 124,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | A | 35,064 | 3 | 104,491 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-07-02 | D | 131,210 | 10 | 1,246,941 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-07-02 | A | 55,979 | 3 | 166,817 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-07-02 | D | 55,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-10-02 | D | 55,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-10-02 | D | 81,056 | 11 | 851,088 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-10-02 | A | 55,979 | 3 | 166,817 | Common | Form 4 ↗ |
| Barry J. Simon | Director | 2026-10-05 | D | 25,000 | 11 | 268,760 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 32 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Barry J. Simon | Director | 2026-06-04 | D | 23,033 | $7 | $165,306 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wesley Clark | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Linda Maxwell | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Wendel | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael D. Blaszyk | Director | 2026-06-09 | A | 65,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry J. Simon | Director | 2026-06-24 | D | 25,000 | 8 | 196,908 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | A | 32,173 | 3 | 95,876 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 33,549 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 32,173 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | D | 95,722 | 9 | 862,216 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | A | 30,000 | 3 | 85,200 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-29 | A | 33,549 | 3 | 100,312 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-30 | A | 700 | 3 | 2,086 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-30 | D | 300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-30 | D | 700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-30 | D | 1,000 | 9 | 9,000 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-06-30 | A | 300 | 3 | 897 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | D | 35,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | D | 159,478 | 9 | 1,439,066 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | A | 124,414 | 3 | 371,998 | Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | D | 124,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christobel Selecky | Director | 2026-07-01 | A | 35,064 | 3 | 104,491 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-07-02 | D | 131,210 | 10 | 1,246,941 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-07-02 | A | 55,979 | 3 | 166,817 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-07-02 | D | 55,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-10-02 | D | 55,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-10-02 | D | 81,056 | 11 | 851,088 | Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-10-02 | A | 55,979 | 3 | 166,817 | Common | Form 4 ↗ |
| Barry J. Simon | Director | 2026-10-05 | D | 25,000 | 11 | 268,760 | Common | Form 4 ↗ |
Sources (73 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Richard Adcock. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 38. As printed: 12,716,953. View filing ↗
- Section 01, Patrick Soon-Shiong. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 38. As printed: 12,293,255. View filing ↗
- Section 01, David Sachs. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 38. As printed: 4,244,543. View filing ↗
- Section 01, Regan Lauer. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 38. As printed: 745,313. View filing ↗
- Section 03, Richard Adcock RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Regan Lauer RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick Soon-Shiong RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Sachs RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Regan Lauer OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Sachs OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Adcock OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick Soon-Shiong OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 69 : 1. View filing ↗
- Section 08, Cheryl L. Cohen. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 514,192. View filing ↗
- Section 08, Michael D. Blaszyk. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 513,384. View filing ↗
- Section 08, Linda Maxwell. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 489,192. View filing ↗
- Section 08, Christobel Selecky. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 477,281. View filing ↗
- Section 08, Wesley Clark. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 470,589. View filing ↗
- Section 08, Bruce Wendel. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 302,740. View filing ↗
- Section 08, John Owen Brennan. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 272,500. View filing ↗
- Section 08, Barry J. Simon. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Patrick Soon-Shiong. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Richard Adcock. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Barry J. Simon 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wesley Clark 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Maxwell 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Wendel 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael D. Blaszyk 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry J. Simon 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christobel Selecky 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry J. Simon 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 98.94% (votes for as printed: 556,683,366). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 467,378 + equity 0 + all other 272,500 = 739,878, summed across the director compensation table rows.
- TG Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. View filing ↗
- BridgeBio Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. View filing ↗
- Blueprint Medicines Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. View filing ↗
- Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- ImmunityBio, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. View filing ↗
- Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Immunocore Holdings plc, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Immunocore Holdings plc's own proxy. As printed: 10,885,268. View filing ↗
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Novavax, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Novavax, Inc.'s own proxy. As printed: 8,856,015. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- Kura Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. View filing ↗
- Fate Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. View filing ↗
- Section 10a, Syndax Pharmaceuticals, Inc. reciprocity. DEF 14A. Syndax Pharmaceuticals, Inc. names ImmunityBio, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗